Director of the Cell Manipulation Core Facility

Director of the Cell Manipulation Core Facility

The Medical Oncology Department at the Dana-Farber Cancer Institute (DFCI) and Brigham and Women’s Hospital (BWH) Department of Medicine is seeking a distinguished physician-scientist (MD or MD/PhD) with an international reputation in cell therapy development and manufacturing, with a primary focus on the treatment of cancer to serve as Director of the Connell and O’Reilly Families Cell Manipulation Core Facility at DFCI.

The mission of the Connell and O'Reilly Families Cell Manipulation Core Facility (CMCF) is to produce safe and effective cellular products for patients enrolled in novel therapeutic clinical research protocols for hematologic malignancies, solid tumors and other diseases. The CMCF is accredited by the Foundation for the Accreditation of Cellular Therapy (FACT) to support the adult and pediatric Stem Cell Transplant and Immune Effector Cell Programs at DFCI, Boston Children’s Hospital (BCH) and Brigham and Women’s Hospital (BWH). As a shared resource of the Dana-Farber/Harvard Cancer Center, the CMCF provides cell manufacturing support for patients enrolled on clinical research protocols at DFCI and Beth Israel Deaconess Medical Center, BCH, BWH and Massachusetts General Hospital. In this context, the CMCF works closely with laboratory investigators, clinical investigators and industry collaborators to manufacture innovative cellular products that are tested in a variety of disease settings.  The CMCF currently employs over 70 full-time staff and supports more than 60 clinical trials and manufactures cellular products for over 20 FDA Investigational New Drug (IND) applications. The current facility, which includes a CLIA certified testing laboratory, encompasses approximately 35,000 square feet dedicated to providing comprehensive support for clinical-scale cell manufacturing.

The individual must be a highly motivated basic scientist or translational investigator with a background in cell manufacturing and an established track-record of academic scholarship in the field of cell therapy. A key priority is ensuring support for innovative investigator-initiated clinical trials of cell therapy. He/she will continually review and ensure that cell manufacturing, delivery and related services are safe, effective and meet the ever-changing clinical needs and research initiatives to support patient-care, primarily within the Harvard-affiliated teaching hospital system in Boston but also including external academic centers and commercial entities.  The individual must have a clear track record and capacity for excellence and leadership in the field of cell therapy development and manufacturing. He or she must have exemplary administrative, mentoring, and communication skills to not only lead a large facility, but also to engage with institutional, departmental, and divisional leaders, as well as the local, national, and international oncology community.

The individual must also have a thoughtful focus on educational opportunities and community interests. The individual must have demonstrated commitment to developing a diverse faculty and staff, with dedication to the recruitment, development, and retention of women and under-represented minorities. 

The position is based in both the Department of Medical Oncology at DFCI and the Department of Medicine at the BWH and includes close collaboration with other institutions affiliated with the Dana-Farber/Harvard Cancer Center and Harvard Medical School.

Applicants should have an MD, PhD, MD/PhD or equivalent degree. The academic appointment will be at the Associate Professor or Professor level at Harvard Medical School and determined by the applicant's credentials. Salary and benefits will be competitive with other institutions. Research and administrative space sufficient to support the new director’s research operation will be provided.

Interested candidates should submit a letter of interest by email along with their CV and the names and email addresses of three references to:

Catherine Wu, MD

Chair, Medical Oncology Search Committee

Dana-Farber Cancer Institute

450 Brookline Ave. DA-0520C
Boston, MA 02215
E-mail: Catherine_Wu@dfci.harvard.edu

Dana-Farber Cancer Institute is an NCI-designated Comprehensive Cancer Center. We are an equal opportunity employer and all qualified applicants will receive consideration for employment without regard to race, color, religion, sex, national origin, disability status, protected veteran status, gender identity, sexual orientation, pregnancy and pregnancy-related conditions or any other characteristic protected by law.

Women and minority candidates are particularly encouraged to apply.